Shenzhen Pregene Biopharma Co. Ltd. has outlicensed its internally developed anti-BCMA CAR T-cell therapy candidate, PRG-1801, to Indian pharma giant Dr. Reddy's Laboratories Ltd. in a $162.5 million deal to develop and commercialize it in India.